IPEC Federation Issues Statement of Phthalate Use - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

IPEC Federation Issues Statement of Phthalate Use


ePT--the Electronic Newsletter of Pharmaceutical Technology

The International Pharmaceutical Excipients Council (IPEC) Federation issued a statement on the use of phthalates in pharmaceutical products in response to reports of adulteration of certain nutritional supplements, vitamins, foods, and beverages imported from Taiwan. Two phthalates, di-ethyl hexyl phthlate (DEHP) and di-isononyl phthalate (DINP), which are commonly used as plasticizers for polyvinyl chloride (PVC)-based plastics, were found in certain adulterated products and subsequently recalled by Taiwan authorities. It is believed that the phthlates were added as a form of economically motivated adulteration as a low-cost replacement for palm oil.

Phthalate-based compounds are used in a variety of industrial, consumer, and pharmaceutical products, and the specific compounds used vary by the targeted application. Certain phthalates, such as di-ethyl phthalate (DEP) and di-butyl phthalate (DBP), are approved for use in pharmaceuticals. “These phthalates can be legally used as plasticizers in drug applications in many countries, and they do not pose safety concerns in these applications,” said the IPEC Federation in its statement.

The adulterated products of concern from Taiwan were produced with emulsifiers manufactured by Yu Shen Chemical Co. and Pin Han Perfumery Co., and were contaminated with the prohibited ingredients, DEHP and/or DINP, plasticizers used in PVC products. Although DEHP may be detected in certain food products as a result of leaching from plastic containers, Taiwanese authorities detected DEHP in various beverages at levels of up to 600 ppm. It is believed that these were added as a form of economically motivated adulteration as a low-cost replacement for the more expensive palm oil. “It is important to stress that the Taiwan incident was limited to only DEHP and DINP and the emulsifier products of concern were only produced by the two companies,” said IPEC in its statement.

In its statement, IPEC said that at this time, only materials originating from the specifically identified manufacturers in Taiwan are at risk. “Drug manufacturers should review their supply chains to determine if they are sourcing emulsifiers that may be implicated in the Taiwanese recalls. To facilitate communication between drug manufacturers and their suppliers, the supply-chain reviews should focus only on the two phthalates of concern, DEHP and DINP,” according to the statement. IPEC issued a list of frequently asked questions in its statement to facilitate the communication between suppliers and drug manufacturers.

Rx-360, a pharmaceutical supply-chain consortium, issued an alert on the DEHP adulteration. IPEC pointed to the two questions noted in the alert that can address the potential risk from the Taiwan incident.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here